Ipamorelin

Ipamorelin Peptide Detailed Overview

Ipamorelin is a highly significant compound within the Growth Hormone axis research bracket, designed to stimulate and analyze the intricate cascades of systemic metabolic regeneration and endocrine pulsing.

Pharmacological Profile

Parameter	Value
Molecular Formula	C38H49N9O5
Molecular Weight	711.9 g/mol
Assay Purity	>99.0%
Appearance	White crystalline powder

Figure 1: Conceptual Binding Mechanism of Ipamorelin

Molecular Methodology

The sequential action framework observed in experimental diagnostics:

1. Selectively occupies the GHSR-1a receptor in the pituitary.
2. Initiates a slow, smooth GH pulse profile resembling natural secretion.
3. Actively avoids stimulating cortisol or prolactin release entirely.
4. Produces virtually zero ghrelin-induced hunger response.
5. Fades cleanly, maintaining immaculate long-term pituitary responsiveness.

Figure 2: Empirical Systemic Response Profile

Identified Research Parameters

• Vector Observation: The cleanest safety and side-effect profile of any GH secretagogue.
• Trial Output: Ideal for extreme long-term use in anti-aging models.
• Diagnostic Core: Synergizes flawlessly with CJC-1295 No DAC without receptor burnout.

The Cleanest Growth Hormone Secretagogue

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a pentapeptide GH secretagogue that is uniquely selective for GH release without stimulating cortisol, aldosterone, prolactin, or appetite at any dose tested. This extraordinary selectivity—unprecedented among GHRPs—results from its specific binding profile at the GHS-R1a receptor, which produces conformational coupling to Gq-mediated GH release without engaging the signaling cascades responsible for ACTH, cortisol, or hunger responses. Ipamorelin is considered the “cleanest” GH secretagogue available.

1. Ipamorelin activates GHS-R1a with high specificity for the calcium/PLC signaling arm that drives GH exocytosis from somatotrophs.
2. Unlike GHRP-6 and GHRP-2, Ipamorelin does not activate corticotroph ACTH release or lactotroph prolactin release at any dose up to 100x ED50.
3. Appetite stimulation is minimal or absent, attributed to biased agonism that favors pituitary GHS-R1a signaling over hypothalamic feeding-center GHS-R1a.
4. GH release is dose-dependent and saturable, with no “ceiling” desensitization observed over 15-day continuous infusion studies in swine.
5. The GH pulse produced by Ipamorelin closely mimics natural GHRH-induced pulsatile release in both amplitude and duration.

Research Advantages & Protocols

• Selectivity: The absence of cortisol, prolactin, and appetite stimulation makes Ipamorelin ideal for research where these confounders must be eliminated.
• Combination Standard: CJC-1295 No DAC + Ipamorelin is the most widely studied GHRH/GHRP combination, producing synergistic GH pulses with a clean hormonal profile.
• No Desensitization: Ipamorelin did not produce GHS-R1a desensitization in the 15-day swine infusion study, unique among GHRPs.
• Veterinary Approval: Ipamorelin is approved in Australia and New Zealand for veterinary use (Ipamorelin-acetate, ZoetaVet) for improving lean meat yield in livestock.
• Dosing: 100–300 μg SC, 1–3 times daily. Commonly dosed pre-bedtime to amplify nocturnal GH pulsatility. Empty stomach recommended.